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Abstract
Background: The authors aimed to conduct an extensive lit-
erature review and consensus meeting to identify unmet 
needs in ulcerative colitis (UC) and ways to overcome them. 
UC is a relapsing and remitting inflammatory bowel disease 
with varied, and changing, incidence rates worldwide. UC 
has an unpredictable disease course and is associated with a 
high health economic burden. During 2016 and 2017, a pan-
el of experts was convened to identify, discuss and address 
areas of unmet need in UC. Methods: PubMed and Cochrane 
Library databases were searched for relevant articles de-
scribing studies performed in patients with UC. These find-
ings were used to generate a set of statements relating to 
unmet needs in UC. Consensus on these statements was 
then sought from a panel of 9 expert gastroenterologists us-
ing a modified Delphi review process that consisted of anon-
ymous surveys followed by live meetings. Results: In 2 litera-
ture reviews, over 5,000 unique records were identified and 
a total of 138 articles were fully reviewed. These were used 
to consider 26 areas of unmet need, which were explored in 
2 face-to-face meetings, in which the statements were de-
bated and amended, resulting in consensus on 30 final state-
ments. The unmet needs identified were categorised into 7 
areas: impact of UC on patients’ daily life; importance of ear-
ly diagnosis and treatment; drawbacks of existing treat-
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ments; urgent need for new treatments; and disease-, prac-
tice- or patient-focused unmet needs. Conclusions: These 
expert group meetings found a number of areas of unmet 
needs in UC, which is an important first step in tackling them 
in the future. Future research and development should be 
focused in these areas for the management of patients with 
UC. © 2019 S. Karger AG, Basel
Ulcerative colitis (UC) is a chronic inflammatory con-
dition causing continuous mucosal inflammation of the 
colon, affecting the rectum and the colon to a variable 
extent [1]. UC primarily presents in late adolescence/ear-
ly adulthood and is characterised by a remitting and re-
lapsing course [1]. The cardinal symptoms of UC are 
bloody diarrhoea, urgency and tenesmus; lower abdomi-
nal pain may also occur [2]. In some patients, the condi-
tion may markedly impact health-related quality of life 
(HRQoL) [3].
Complete remission of UC is defined as clinical as well 
as endoscopic remission, with macroscopic healing of the 
mucosa [4]. Mucosal healing is an important predictor of 
long-term outcomes of treatment [4].
5-Aminosalicylic acid (5-ASA) may be used to induce 
remission in mild-to-moderate UC [5]. In patients who 
fail to respond to 5-ASA and those with more severe 
disease, corticosteroids may be an option [6]. For non-
responders to corticosteroids treatment options include 
infliximab, ciclosporin, tacrolimus or surgery [5]. Thio-
purines (azathioprine or mercaptopurine) may be useful 
in patients with corticosteroid-dependent disease [6]. 
5-ASA may successfully maintain remission in respond-
ers to this agent, whereas remission induced by cortico-
steroids should be maintained by 5-ASA or, when clini-
cally necessary, a thiopurine derivative [4]. Tumour ne-
crosis factor (TNF) inhibitors, alone [7–10] or in 
combination with thiopurines [11], or the anti-integrin 
vedolizumab [12] may be used to induce and maintain 
remission in patients who are refractory to the above ap-
proaches. Patients who do not initially respond, or lose 
response, to a TNF inhibitor or vedolizumab may be 
switched to a different drug with another mechanism of 
action (swap) or the same target (switch) [4]. Surgery 
may be considered in a number of difficult clinical sce-
narios [5]. Reconstructive surgery with ileoanal pouch 
anastomosis is the surgical procedure of choice per-
formed in patients with intractable disease or its com-
plications. While usually associated with improvement 
in QoL, ileoanal pouch anastomosis may also impart 
substantial morbidity such as pouchitis and the poten-
tial for pouch failure in approximately 5% of patients 
[13, 14].
Despite considerable advances in the knowledge of UC 
and the availability of a range of treatment options for the 
many clinical presentations of this greatly heterogeneous 
condition, in practice, gaining a satisfactory outcome for 
all patients remains elusive. The extent of unmet need in 
UC patients who exhibit an inadequate response, lose re-
sponse or cannot tolerate available treatments is not 
widely understood [15].
There are areas of unmet need beyond those relating 
to improving treatment and achieving remission. A high 
incidence of UC in many European countries, North 
America, Australia and New Zealand [16] results in a high 
cost burden associated with the disease. While rising costs 
of medication may coincide with a reduction in costs as-
sociated with hospital admissions and surgery, the overall 
cost burden is high. One estimate places the annual cost 
of treating UC to healthcare systems across Europe at 
EUR 4.6–5.6 billion [17].
UC has an unpredictable natural history. The unpre-
dictability of the disease and the lack of robust predictive 
biomarkers at UC onset strongly affect patient-reported 
outcomes (PROs) and the impact of the disease [18]. Cur-
rent standards of care stratify patients by their disease ex-
tent, severity and response to treatment according to a 
“step-up” approach that begins with the least toxic treat-
ments first [18–20].
Much of the literature emphasises positive disease out-
comes, often related to the meeting of pre-defined study 
criteria. Such reports provide valid and useful data, but 
may fail to address areas of unmet need. Defining those 
unmet needs that exist in the care of patients with UC is 
an important step towards the development of strategies 
and allocation of resources to overcome them and opti-
mise patient quality-of-life and quality-of-care.
Against this backdrop of unmet medical needs in the 
management of UC, as well as increasing prevalence, 
high health-economic burden and unpredictable dis-
ease course, a group of 14 gastroenterologists met to 
define, characterise and prioritise unmet needs in the 
management of UC. Based upon a systematic review of 
recent scientific literature, and using a modified Delphi 
process, the panel identified and agreed 18 unmet needs 
consensus statements. In addition to these statements, 
the panel proposed 11 additional areas of unmet need 
that fell outside of the scope of that meeting (Table 1) 
regarding the natural history of UC, current practice in 
the treatment of UC, and patients’ views on the man-
agement of UC. Based on these proposed additional un-
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met needs, a second panel was convened in April 2017. 
The aim of this meeting was to, based on a new review 
of the literature, define, characterise and prioritise these 
11, and any additional relevant, unmet needs. The con-
sensus-building process and conclusions of the 2 Un-
met Needs in UC Expert Panel meetings are presented 
herein.
Methods
Unmet Medical Needs in UC
Literature Review
To investigate unmet needs in the treatment of UC, exten-
sive literature reviews were performed. PubMed and Cochrane 
Library databases were searched for references published since 
January 1, 2006 and May 2016 (however, important articles 
published later could be included during panel discussion – see 
below). Articles were restricted to English language publica-
tions and studies conducted in humans. Searches were per-
formed in the format “UC AND secondary term”. Secondary 
search terms included drug names and drug classes used in the 
treatment of UC (online suppl. Table 1, see www.karger.com/
doi/10.1159/000496739) and a list of relevant terms extracted 
from a recent systematic review by Linstone et al. [21] supple-
mented by the panel’s personal experiences. Titles or abstracts 
were reviewed for relevance; publications were then screened 
for the following exclusion criteria: findings superseded by 
newer data; small study (< 40 participants); single-centre stud-
ies; paediatric patients; not specifically investigating UC; or ob-
jective not aligned with the present search.
The results of the literature review were used to generate a pre-
liminary set of statements that formed the basis of the question-
naire for the first round of the Delphi process.
Table 1. Preliminary statements and initial survey results
Statement Preliminary wording Median 
score
IQR Consensus 
achieved
1 Improvements in time to diagnosis and timely, effective intervention
have the potential to improve outcomes
8 7–9 Yes
2 Extensive disease at diagnosis is associated with poor prognosis 8 7–8.75 Yes
3 Prolonged exposure to corticosteroids is associated with side effects
that  outweigh the clinical benefits
9 9 Yes
4 TNF inhibitors have improved remission rates in UC, but one third to one
half of patients do not respond due to primary or secondary non-response
8.5 7.25–9 Yes
5 Anti-integrins provide an alternative to TNF inhibitors but comparative
efficacy is unknown
9 8–9 Yes
6 Alternative agents with a rapid onset of clinical effect would be of value in 
 ulcerative colitis
9 9 Yes
7 A proportion of patients would benefit from additional treatment options
when currently available therapies fail or are not tolerated
9 8–9 Yes
8 Hospitalisation rates and surgical interventions have reduced with the
advent of biologics, but further improvements can be made
8 7–9 Yes
9 Patients prefer oral vs. parenteral formulations 8 7–8 Yes
10 Ulcerative colitis patients have a reduced quality of life 7 7–9 Yes
11 There is a gap between patient and caregiver perceptions in UC 8 7–9 Yes
12 Conventional therapies (ASAs, corticosteroids, immunosuppressants and 
 antibiotics) effectively treat symptoms of UC but are often associated with
lack of response or intolerance 
6 3.25–7.75 No
13 TNF inhibitors may require dose escalation and therapeutic drug monitoring 8 6.25–9 No
14 Adherence to self-administered treatments in UC is poor 6 5–8 No
15 A proportion of UC patients have a reduced ability to work 7 5.25–9 No
ASAs, aminosalicylic acids; IQR, interquartile range; TNF, tumour necrosis factor; UC, ulcerative colitis.
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Survey Participants
The expert panel comprised 14 gastroenterologists with exper-
tise in IBD from 13 European countries. All members of the panel 
participated in the Delphi survey.
Delphi Process
The Delphi method was developed to enable the exploration of 
complex problems through structured group communication [21]. 
It is an evidence-based approach that allows a group of individuals 
to explore issues surrounding a problem, establishing the advan-
tages and disadvantages of different arguments, through the use of 
surveys and a final live meeting [22]. The process involves the for-
mation of a steering committee responsible for identifying issues 
surrounding the problem in question, development of relevant sur-
vey questions and recruitment of a panel of experts to participate 
anonymously in the survey. In the present case, 1 round of anony-
mous completion of the survey was followed by a live meeting dur-
ing which individual survey responses remained anonymous to 
preserve objectivity.
In round 1, an anonymous questionnaire invited respondents 
to score each of the preliminary statements derived from the lit-
erature review results on a 9-point Likert scale (ranging from 1, 
strongly disagree to 9, strongly agree). Then, median scores and 
interquartile ranges (IQR) from the group were calculated for each 
statement: an IQR 7 and above represented a positive consensus; 
IQR 3 or less inferred negative consensus; and IQR above 3 and 
less than 7 was considered a neutral opinion.
In round 2, the respondents met to review the results of round 1 and 
revise wording of the statements where appropriate. For statements 
that reached positive consensus in round 1, wording could still be re-
vised following discussion. For statements that did not gain consensus, 
supporting data were reviewed, wording was amended as required and 
revised statements were scored. Further statements added as a result of 
discussion during the meeting were subsequently put to vote.
Disease-, Practice- and Patient-Focussed Unmet Needs in UC
Literature Search
During the debate surrounding unmet medical needs in UC, a 
number of additional unmet needs statements were discussed, 
which were not related to UC management. In order to develop an 
evidence-based consensus on these additional statements, a simi-
lar process was followed.
Three literature searches were conducted using PubMed, using 
the same format of “UC”, combined with a number of secondary 
search terms from the discussions at the first panel meeting. The 
search was conducted for articles published between January 1, 
2006 and April 1, 2017, and was restricted to English language ar-
ticles and those involving human subjects. Different secondary 
search terms were used for each literature search (Table 2).
The combined results were subject to the following exclusion 
criteria: superseded by newer data; small or single-centre studies; 
paediatric UC; not specifically concerning UC; objective not 
aligned with search. The titles of the remaining articles were then 
screened for relevance. Abstracts of those articles considered po-
tentially relevant were then assessed for eligibility, with the full text 
of those articles remaining subsequently assessed.
The results of the literature review were then used to refine the 
initial proposed unmet needs statements. The resulting statements 
formed the basis of a pre-meeting survey for the first round of a 
new Delphi process.
Survey Participants
The panel comprised 9 leading European gastroenterologists 
with expertise in IBD. All participants took part in the survey.
Table 2. Search terms utilised in the three separate literature searches
Primary search 
term
Secondary search terms
From initial unmet needs statements From refined unmet needs statements Additional
UC Unmet need Real world data Steroid free response
Patient preference Real world evidence Endoscopic remission
Quality of life Patient perspective Histologic remission
FDA Employment Sustained remission
PRO Absenteeism Sustained response
Empowerment Steroid-free remission Clinical remission
Strategy Mucosal healing Treatment decision making
Treatment Loss of response Clinical decision making
Treatment guideline Prognostic biomarkers Course of disease
Therapeutic biomarkers Nature of disease
Coping behaviour DMAID
Adaptation Disease modifying
Clinical practice Natural history
Long term remission
Clinical trial
Effectiveness
DMAID, disease-modifying anti-inflammatory bowel disease drug; FDA, food and drug administration; PRO, patient-reported 
outcomes; UC, ulcerative colitis.
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Delphi Process
As with the unmet medical needs consensus-building process, 
a modified Delphi process was utilised, consisting of 2 rounds: a 
survey followed by a live meeting.
The unmet needs statements developed as outputs of the lit-
erature search were sent to the 9 members of the Expert Panel as a 
survey, to ascertain their level of agreement with each statement.
The second round of the modified Delphi process saw the con-
vening of the panel to review the unmet needs statements and the 
varying degrees of agreement reached through the survey. Indi-
viduals were afforded the opportunity to modify their survey re-
sponses in light of the group discussion, with discussions aiming 
to achieve consensus, again following the same process previously 
used. Once consensus on all statements had been reached, they 
were prioritised.
Results
Unmet Medical Needs in UC
Literature Search
After removal of duplicates, the titles or abstracts of 
2,364 publications were reviewed for relevance. In all, 
2,138 publications were deemed not relevant and ex-
cluded; of the remaining 226 publications, 92 were fi-
nally included for full review after application of exclu-
sion criteria (PRISMA diagram; Fig. 1). These litera-
ture review findings were used to generate a total of 15 
preliminary statements that were the basis of the ques-
tionnaire used in the first round of the Delphi process.
Survey Results
During the first round of scoring, consensus was 
reached on 11 of the 15 preliminary statements; no con-
sensus was reached on the remaining 4 statements (Table 
1). Following discussion, wording was revised for 8 of the 
11 statements for which consensus was reached. Follow-
ing discussion of the 4 statements for which no consensus 
was reached, one of the statements was divided into 2 sep-
arate statements, for both of which consensus was then 
reached; wording was revised on the remaining 3 state-
ments, which then gained consensus.
During the meeting, an additional 14 areas of unmet 
need were proposed; of these, following discussions, the 
Records identified
through PubMed
(n = 2,364)
Records screened after
duplicates removed
(n = 2,364)
Records excluded
(n = 2,138)
Records excluded
(n = 134)
Total records identified
(n = 2,387)
Additional records
(n = 5)
Records identified
through cochrane
(n = 23)
Full text articles assessed
for eligibility
(n = 226)
Full text articles assessed
for eligibility
(n = 226)
Studies prioritised for
data extraction
(n = 92)
Studies used in qualitative
synthesis (generate
statements)
(n = 47)
In
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d
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y
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Fig. 1. PRISMA diagram showing the flow 
of steps in published data collection.
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group agreed to take forward 3 statements for further 
consensus development. Subsequently, consensus was 
reached for 2 of these 3 additional statements. Ultimately, 
18 statements reached consensus (Table 3a–d). These 
statements could be categorised into 4 areas: impact of 
UC on patients’ daily life; importance of early diagnosis 
and treatment; drawbacks of existing treatments; and 
need for new treatments.
Unmet Needs Statements: In Four Categories
UC Impacts Patients’ Ability to Lead a Normal Life (Ta-
ble 3a). Overall, UC patients can achieve levels of HRQoL 
comparable to norms for the general population [3]. 
However, ongoing presence of symptoms, use of cortico-
steroids, unemployment, female sex and smoking may be 
associated with reduced HRQoL in patients with UC [3]. 
UC in general is associated with a high prevalence of fa-
tigue (44%), severe depressive symptoms (14.9%) and im-
pairments in sexual function (20.6%) [23]. Treatment 
regimens requiring multiple daily dosing can interfere 
with patients’ daily life, negatively affecting adherence to 
therapy and leading to poorer long-term outcomes in UC 
[24]. Biologics have the potential to improve HRQoL 
[25].
With regard to the workplace, UC is associated with 
increases of up to 88% in absenteeism, 69% for sick leave, 
66% for reduced capacity, 50% for unemployment and 
19% for disability pension – with the risk for receiving a 
disability pension highest in the 18–39-year age group 
[26, 27]. Moreover, many patients undergoing colectomy 
persistently have work disability after the surgery, possi-
bly due to long-term postoperative complications [27]. 
On the other hand, biologic agents have shown positive 
effects on improving absenteeism and presenteeism at 
work [26]. In a recent meta-analysis of randomised trials 
data, the TNF inhibitors infliximab and adalimumab were 
more effective than placebo in reducing the rate of UC-
related hospitalisation, whereas treatment with inflix-
imab (but not adalimumab or golimumab) was associated 
with a reduced rate of colectomy at 54 weeks [28]. Some 
researchers have reported that biologics apparently had 
no impact on hospitalisation and colectomy rates [29, 30], 
Table 3. Unmet medical needs in UC: expert panel statements (in 4 categories, a–d)
a. UC impacts patients’ ability to lead a normal life
– A significant proportion of UC patients have reduced quality of life
– A proportion of UC patients have reduced ability to work
– Colectomies and hospitalisation rates are declining in the era of biologics, but further improvements can be made
– There is a gap between patient and caregiver perceptions in UC
b. Early diagnosis and treatment are important
– Reduction in time to diagnosis and timely, effective intervention have the potential to improve outcomes
– Extensive disease and/or severe disease activity at diagnosis are associated with poor prognosis
– Patients with proctitis require early and effective treatment to improve their quality of life over the long term
c. Existing therapeutic options have significant drawbacks
– Adherence to self-administered treatments in UC is poor
–  Prolonged exposure (over 3 months) to, or repeated courses of, corticosteroids is/are associated with side effects that outweigh the 
clinical benefits
– Aminosalicylates may effectively treat UC, although they may be associated with lack of efficacy in some patients
– Thiopurines may effectively treat UC, although they may be associated with lack of efficacy and/or intolerance in some patients
– TNF inhibitors may require dose escalation and therapeutic drug monitoring to optimise treatment
–  TNF inhibitors have improved remission rates in UC. One third of patients are primary non-responders and up to one half exhibit 
secondary loss of response
– Anti-integrins provide an alternative to TNF inhibitors, but comparative efficacy is unknown
d. There is a need for new therapeutic options
– Patients would benefit from additional treatment options to improve disease control and outcomes
– Alternative agents with a rapid onset of clinical effect would be of value in moderate-to-severe UC
– Patients usually prefer oral vs parenteral formulations of drugs with a comparable efficacy and safety profile 
–  European IBD societies should collaborate with stakeholders and lobby for continued investment in the education of HCPs and 
raise awareness of the treatment of UC through development, publication and dissemination of scientific research
HCPs, healthcare providers; IBD, inflammatory bowel disease; TNF, tumour necrosis factor; UC, ulcerative colitis.
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whereas a recent focus paper by the Epidemiology Com-
mittee of European Crohn’s and Colitis Organisation 
(ECCO) concluded that colectomy rates have dropped 
since the introduction of these drugs, but conceded that 
data on hospitalisations is heterogeneous and conflicting 
[31]. Future studies involving an extended follow-up pe-
riod are required to answer this question definitively.
Patients and caregivers (physicians/nurses) differ in 
their perceptions of disease severity. In general, disease 
severity estimated by physicians was milder than was self-
reported by patients; also, physicians estimated fewer 
flares and better overall quality of life than was self-re-
ported by patients [32–34]. Both patients and caregivers 
do agree, however, that more regular interpersonal con-
tact between them would have a positive impact on im-
proving UC management [35].
Early Diagnosis and Treatment Are Important (Table 
3b). Extensive UC involvement at diagnosis is associated 
with a severe disease course; extensive disease (Montreal 
E3; pancolitis) on the initial endoscopy was more fre-
quent in patients with moderate-to-severe UC (rate of 
proximal disease location in mild, moderate and severe 
UC: 13, 21 and 30%, respectively; p = 0.001) [36]. Deep 
ulceration at colonoscopy is associated with poor progno-
sis [1]. Proctitis is a common feature of UC, with over 
30% of patients presenting with disease limited to the rec-
tum [37]. Proximal disease extension has been observed 
in over 28% of UC patients after a median of 10 years of 
follow-up [38]. Therefore, early and effective treatment of 
proctitis is needed. It is noteworthy that patients with 
proctitis have been excluded from most prospective ran-
domised controlled trials [9, 10, 12, 39], and the effects of 
the majority of systemic treatments have not been spe-
cifically investigated in UC proctitis.
Rapidity of achieving remission as well as its sustain-
ability are likely important factors in attaining treatment 
goals in UC [40]. In this regard, remission was achieved 
within 2 weeks following a single dose of infliximab in 
27% of patients and a similar early response rate was ob-
served for adalimumab [40]. The remission rate in UC 
patients treated with golimumab and vedolizumab was 
lower but comparable to that with infliximab and adali-
mumab: remission was achieved by 18% of patients re-
ceiving golimumab [9], whereas 17% of patients treated 
with vedolizumab entered clinical remission by week 6 
[12].
Ultimately, remission may be defined as clinical im-
provement, mucosal healing, histologic healing and cor-
rection of the underlying immunological defect [40]. Al-
though the progressive nature of UC is less certain than 
for Crohn’s disease (CD), inadequately treated inflamma-
tion in UC is believed to enhance the risk of dysplasia and 
colon cancer. However, whether UC is associated with an 
increased long-term risk of death compared with the gen-
eral population is debatable [41–43].
Existing Therapeutic Options Have Significant Draw-
backs (Table 3c). A large number of clinical trials of 5-ASA 
in a variety of oral and topical formulations, mainly con-
ducted in the 1980s–90s, have long-since established this 
drug as gold standard therapy for induction and mainte-
nance of remission in mild-to-moderate UC [44]. How-
ever, long-term persistence with 5-ASA may be problem-
atic, especially if corticosteroid courses are co-medicated 
(see below).
Corticosteroids have demonstrated good efficacy in 
inducing rapid clinical responses; however, these drugs 
are associated with significant unwanted side effects [45] 
and their use in UC patients may confer a hazard ratio for 
death of 2.81 (95% CI 2.26–3.50) versus age-matched 
healthy controls over a 10-year period [42]. “Corticoste-
roid-free remission” is the common aim of clinical guide-
lines for the management of UC [4, 5]. Immunomodula-
tors in the setting of maintenance therapy refractory to 
5-ASA or corticosteroid-dependent disease are associat-
ed with high rates of switching and augmentation with 
add-on therapies; in one large real-world population 
study in the United States, 30% of patients experienced 
post-exposure complications during their index immu-
nomodulator therapy and 73% relapsed while on treat-
ment [46]. The 2016 ECCO guidelines recommend that 
only immunomodulators be used in refractory disease or 
in combination with TNF inhibitors, as the superior ef-
ficacy of infliximab in combination with azathioprine in 
steroid-refractory disease has been demonstrated [5].
In patients in whom corticosteroids are required to 
achieve remission, approximately 20% still require corti-
costeroid therapy at 1-year post-initiation [47]. Among 
126 such “corticosteroid-dependent” patients who were 
switched to infliximab, half remained corticosteroid-free 
and without colectomy at 6 and 12 months. Significant 
predictors of maintaining corticosteroid-free remission 
in these individuals were co-medication with azathio-
prine and normalisation of C-reactive protein levels fol-
lowing switch to infliximab [47].
Primary failure of anti-TNF induction therapy occurs 
in 19–58% of patients in clinical trials [15]. In a meta-
analysis of trials data on anti-TNF therapy using adalim-
umab, golimumab or infliximab the relative risk of achiev-
ing short- (6–8 weeks) and long-term (52–54 weeks) re-
mission of UC favoured all 3 drugs at all doses tested 
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versus placebo, with the 95% CIs mostly demonstrative of 
reaching a statistically significant difference [28]. How-
ever, the combined proportion of patients who achieved 
remission on these 3 TNF inhibitors was only 23% in the 
short term and 26% in the long term; by comparison, in 
patients receiving placebo the rates were 7.4 and 12.5%, 
respectively, at the same time-points. Real-life remission 
rates with TNF inhibitors in UC are also low overall; less-
er than one quarter patients achieve greater than 3-month 
clinical remission on these drugs [48].
In addition to primary failures, some patients who ini-
tially respond to TNF inhibitor therapy will eventually 
discontinue due to secondary loss of response (17–22%) 
or toxicity (< 10%), and 19–40% of patients will require 
dose escalation to maintain efficacy [15]. Patients treated 
with TNF inhibitors have only a 1.76-fold (95% CI 1.46–
2.14) higher likelihood of maintaining response for at least 
52 weeks compared with those assigned to receive placebo 
[49]. Secondary loss of response to TNF inhibitors may be 
successfully overcome by increasing drug exposure (in-
creasing dose or reducing dosing interval) or switching to 
another drug [50]. However, evidence suggests that treat-
ment failure is even higher among patients undergoing 
second-line TNF inhibitor therapy; in a meta-analysis of 
studies in these individuals, the proportion who discon-
tinued treatment due to loss of response was 68–77% by 
the end of year 1 and 82–90% by the end of year 2 [15].
For patients who experience primary or secondary 
treatment failure with anti-TNF agents, switching to a 
biologic with a different mechanism of action may be ap-
propriate. Vedolizumab is a monoclonal antibody target-
ing α4β7 integrin leading to gut-selective inhibition of 
immune cell recruitment and thereby exerts anti-inflam-
matory activity in UC [15]. Vedolizumab has been dem-
onstrated statistically and significantly to be more effec-
tive than placebo in terms of clinical response rate, main-
tenance of remission and mucosal healing [12, 51]. 
Moreover, long-term clinical study data in over 2,800 
IBD patients who were treated for up to 5 years demon-
strate that this drug has a favourable safety profile with 
no increased risk of serious or opportunistic infections 
or malignancy versus placebo [52]. Head-to-head com-
parative studies of vedolizumab versus TNF inhibitors 
are needed [53].
Adherence to UC treatments, including 5-ASA, is of-
ten poor and non-adherence is associated with enhanced 
risk of relapse [54]. 5-ASA and azathioprine seem to have 
particularly poor rates of adherence, with patients on 
these drugs missing 45 and 25%, respectively, of their to-
tal prescribed doses – mostly involuntarily due to forget-
fulness [55]. Recently, once-daily dosing for 5-ASA has 
gained popularity and this strategy has been demonstrat-
ed to improve adherence over thrice-daily dosing, with 
non-inferior efficacy, in one UC series [56]. A systematic 
review evaluating adherence to anti-TNF therapy in IBD 
reported a pooled rate of 82.6% (83.1% in adalimumab 
and 70.7% in infliximab-treated patients) [57].
There Is a Need for New Therapeutic Options (Table 3d). 
In clinical practice, there remains a high rate of incomplete 
or non-response to UC medications, indicating a need for 
new therapeutic strategies [58]. Moreover, in a survey of 
256 moderate-to-severe UC patients from 11 European 
countries, 48% were dissatisfied with their current treat-
ment [34]. Effectiveness, long-lasting action, rapid onset 
of action and few side effects were considered important 
or very important by this cohort of patients [34].
Up to one third of patients receiving 5-ASA are not 
satisfied with this therapy [33]. However, only a small 
proportion of UC patients may complain of treatment 
dissatisfaction with their doctor [32]. Patients’ decisions 
when selecting a TNF inhibitor are influenced by ease of 
medication use, time required to take treatments, time 
interval between drug dosing, scientific evidence for ef-
ficacy and fear of syringes [59]. A cross-sectional study of 
patients enrolled at the IBD unit of a French hospital re-
vealed that those receiving infliximab spent 6.5 h away 
from home or work for each infliximab infusion [60]. For 
oral therapy, UC patients prefer medications that present 
no swallowing difficulties, are taken once daily and have 
fewer tablets per dose regimen [55].
New drug classes such as JAK inhibitors, which reduce 
the expression of a number of inflammatory cytokines 
implicated in UC, including tofacitinib, filgotinib and 
upadacitinib (all in phase III clinical trials), and T cell-
inhibitory S1P receptor modulators, such as ozanimod 
(also in phase III) offer potential therapeutic benefits in 
UC [61].
Disease-, Practice- and Patient-Focussed Unmet Needs 
in UC
Literature Search
Following the completion of the first unmet needs in 
UC consensus-finding exercise, evidence relating to the 
additional unmet needs suggested during the first panel 
meeting was sought through additional literature search-
es. A combined total of 2,817 articles were identified. 
These were cross-checked for duplicates and the exclu-
sion criteria applied, before being screened for relevance 
and assessed for eligibility (Fig. 2). A total 46 articles were 
deemed appropriate for inclusion, and these were utilised 
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to assess the 11 preliminary unmet needs statements. This 
assessment resulted in an expanded set of 14 unmet needs 
statements across 3 categories: disease-focused unmet 
needs; therapy-focused unmet needs, and patient-fo-
cused unmet needs. These statements were included in 
the survey for distribution to the experts that formed 
round 1 of the modified Delphi process.
Delphi Process
The round 1 survey of unmet needs statements saw 
consensus being reached for 10 of the 14 statements (Ta-
ble 4). All statements were individually and comprehen-
sively discussed during the Expert Panel meeting that 
formed round 2 of the process. Those statements that had 
not reached consensus during the round 1 survey were 
further refined and voted upon again. This process pro-
duced a prioritised set of 12 unmet needs statements 
across a refined set of categories: disease-focused; prac-
tice-focussed, and patient-focused. Consensus was not 
reached during the meeting for 1 statement. Subsequent 
to the meeting, this statement was refined and put to an 
online vote, achieving consensus at that time. All unmet 
needs statements can be seen in Table 5.
Unmet Needs Statements
Disease-Focused Unmet Needs Statement
1. There are gaps in the current understanding of the 
natural history of UC. Heterogeneity pervades all aspects 
Unique records
identified from
initial literature
search
(n = 1,999)
Unique records
identified from
refined literature
search
(n = 855)
Unique records
identified from
additional literature
search
(n = 691)
Records identified from all literature
searches
(n = 3,575)
Records
excluded
(n = 758)
Records
excluded
(n = 2,434)
Records
excluded
(n = 107)
Records
excluded
(n = 230)
Records after duplicates removed and
exclusion criteria applied
(n = 2,817)
Titles screened for relevance
(n = 2,817)
Abstracts assessed for eligibility
(n = 383)
Full text articles assessed for eligibility
(n = 276)
Studies utilised to refine unmet
needs statements
(n = 46)
In
clu
de
d
Eli
gi
bi
lit
y
Sc
re
en
in
g
Id
en
tif
ica
tio
n
+ +
Fig. 2. PRISMA diagram showing the flow 
of steps literature search.
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of UC, from incidence rates around the world to disease 
course in individual patients.
Geographically, incidence rates of UC vary consider-
ably in different parts of the world, and these rates ac-
cording to time period and location studied, with dif-
ferent rates in Asia [20] and Europe, for example [16, 
17].
Clinically, variation between individuals is seen from 
the time of diagnosis [62], with some patients presenting 
with intermittent flares while other exhibit chronic symp-
toms. The disease course of UC may differ between pa-
tients [62]. Symptoms associated with UC can obviously 
impair patient quality of life, while the underlying inflam-
mation may lead to the progression of disease extent, col-
ectomy and/or the development of colitis-associated 
colorectal cancer, with varying levels of risk associated to 
some of these outcomes in different geographies [62]. The 
pathophysiology of disease, as well as genetic or environ-
mental factors underlying these disparate observations, is 
not yet fully understood.
Approaches to the treatment of UC are changing, 
with a growing emphasis on the use of immunosup-
pressant and biologic therapies. However, the impact 
of these drugs on the natural history of UC is poorly 
understood at present [62, 63]. In addition, further 
knowledge of the pathophysiology of UC will be critical 
to the future development of novel therapeutic targets 
[64].
Practice-Focused Unmet Needs Statements
2. For a substantial proportion of patients there is an 
unmet need for treatments that improve the natural his-
tory of UC. During the early stages of UC, relapses are 
associated with a hastening of disease progression [65]. 
Patients who regularly use oral aminosalicylates are 5.8 
times more likely to experience disease regression than 
Table 4. Preliminary unmet needs statements and results of round 1 survey
Statement Preliminary wording Median 
score
IQR Consensus 
achieved
Disease-focused
1 There are gaps in the current understanding of the natural history of UC 8 7–8.5 Yes
2 There is a need for accurate prognostic biomarkers in UC 8 7.5–9 Yes
Therapy-focused
3 There is an unmet need for treatments that modify the natural history of UC 8 7.5–8 Yes
4a The ideal treatment strategies should include well-defined treatment algorithms 7 6.5–8 No
4b Targets of ideal treatment should be defined and agreed upon. The following should be 
 treatment targets:
i. Induction and maintenance of steroid-free remission 
ii. Long-term remission
iii. Mucosal healing
iv. Avoidance of the need for colectomy
v. Minimise loss of response
9 6.5–9 No
4c Ideal treatment strategies should be reflected in the current treatment guidelines 8 5.5–8 No
4d There is an ongoing need to update treatment guidelines to reflect the introduction of  
novel UC therapeutics
8 7–8.5 Yes
4e Current healthcare practice does not always reflect ideal treatment strategies 8 7–9 Yes
5 There is a need for accurate predictive biomarkers for the efficacy of therapies in UC 8 7.5–9 Yes
Patient focused
6 The determinants of patients’ perspectives on their diseases are poorly understood 7 7–8 Yes
7 Patient-reported outcomes need to be defined and validated to provide comparable  results 
across studies
8 8–8.5 Yes
8 Patient-reported outcomes need to be used more consistently in clinical trials 8 8 Yes
9 Increased involvement of patients in clinical decision making improves treatment  outcomes 7 6.5–8 No
10 Patient adaptation to symptoms can result in reduced expectations from therapeutics and 
treatment management
8 7–8 Yes
IQR, interquartile range; UC, ulcerative colitis.
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those who do not [65], and oral aminosalicylates may 
also protect against the proximal extension of mucosal 
inflammation in UC [65]. This suggests a disease-modi-
fication role for oral aminosalicylates in UC [65]. There 
is also evidence that thiopurines and anti-TNF treat-
ments have the potential for disease modification in UC 
[63, 66]. The term “disease-modifying anti-rheumatic 
drugs” is widely used in the field of rheumatoid arthritis, 
and it is possible that a similar concept could be adopted 
in IBD [66]. Possible terms for the use of disease modify-
ing agents such as oral aminosalicylates or anti-TNFs in 
UC might be “disease-modifying anti-inflammatory 
bowel disease drugs” or “intestinal damage-preventing 
anti-UC drugs” [63]. The latter would imply that these 
drugs control inflammation and thereby minimise com-
plications such as dysplasia and cancer. The aim of treat-
ing UC using disease-modifying drugs, beyond the goals 
of improving symptoms and inducing remission, would 
be to prevent extended and permanent effects of disease 
activity, such as bowel damage and the need for colec-
tomy [66].
3a. There is a current unmet medical need to define and 
achieve optimal treatment goals in UC. These include:
i. Improvement of quality of life
ii. Minimisation of adverse events
iii. Reduction of tissue damage
iv. Reduction of hospitalisation
v. Reduction of colectomy rates
vi. Reduction of incidence of cancer
3b. To achieve these goals, treatment targets should be 
defined and include:
i. Induction and maintenance of long-term steroid-
free remission
ii. Resolution of mucosal inflammation
According to the 2016 ECCO UC management guide-
line, the goal of maintenance therapy is steroid-free re-
mission, defined both clinically and endoscopically [1]. 
The purpose of maintaining clinically defined steroid-
Table 5. Unmet needs in ulcerative colitis: 2nd expert panel statements in 3 categories
Disease-focused unmet needs
1 There are gaps in the current understanding of the natural history of UC
Practice-focused unmet needs
2 For a substantial proportion of patients there is an unmet need for treatments that improve the natural history of UC
3a There is a current unmet medical need to define and achieve optimal treatment goals. These include:
i. Improvement of quality of life
ii. Minimisation of adverse events
iii. Reduction of extent of tissue damage
iv. Reduction of hospitalisation
v. Reduction of colectomy rates
vi. Reduction of incidence of cancer
3b To achieve these goals, treatment targets should be defined and include:
– Induction and maintenance of long-term steroid-free remission
– Resolution of mucosal inflammation
4 There is a need to bridge the existing gap between current healthcare practice and optimal treatment strategies
5 There is a need for accurate biomarkers to assist selection of the most appropriate therapies in UC
6 There is an ongoing need to update treatment strategies including the introduction of novel UC therapies
7 Optimal treatment strategies should take into account recommendations and guidelines
Patient-focused unmet needs
8 PROs beyond stool frequency and rectal bleeding need to be defined and validated to provide comparable results across studies
9 Patients’ perspectives and expectations are poorly understood
10 Active involvement of patients in clinical decision making improves patient satisfaction and probably disease outcomes
11 Patients may reset their tolerance threshold to the symptoms and this can result in lower treatment expectations
PROs, patient-reported outcomes; UC, ulcerative colitis.
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free remission is to improve patient quality of life and 
avoid the complications of prolonged steroid use. Endo-
scopic remission is predictive of good outcomes; in addi-
tion to improving symptoms, maintaining endoscopic re-
mission is associated with reduced colorectal cancer inci-
dence, with macroscopically normal looking colonoscopy 
considered to be associated with reduced cancer risk [67].
Histologic remission is distinct from endoscopic mu-
cosal healing and histology may have a higher sensitivity 
than endoscopy for epithelial damage and risk of relapse 
[1]. It is associated with freedom from symptoms, low-
ered risk of relapse and reduced hazard for surgery, hos-
pitalisation and colorectal cancer in patients with UC 
[68]. Currently, however, no standard definition of histo-
logical remission exists and it is not currently recom-
mended as a goal in daily clinical practice [1].
4. There is a need to bridge the existing gap between cur-
rent healthcare practice and optimal treatment strategies 
in UC. The treatment decisions made by IBD care provid-
ers in daily practice are often different from those recom-
mended by experts or supported by latest research out-
comes. In addition, gastroenterologists may experience 
difficulty in assessing disease activity or severity as rec-
ommended by guidelines, and in applying treatment rec-
ommendations, in daily practice [69]. A survey conduct-
ed with community gastroenterologists and UC experts 
in the United States identified that, when it came to areas 
of uncertainty in UC treatment, dramatic variations in 
approach existed between the 2 groups [70].
Where a gulf exists between recommendations and 
clinical practice, this may be owing to limitations within 
healthcare systems, financial constraints or poor patient 
adherence to treatment regimens.
5. There is a need for accurate biomarkers to assist selec-
tion of the most appropriate therapies in UC. Biomarkers 
in UC are necessary for accurately predicting the efficacy 
of specific therapy choices and assessing prognosis. While 
there have been advances in the molecular fingerprinting 
of UC, very few validated biomarkers exist, either in the 
gut mucosa or body fluids [71], and so the need remains 
for reliable, cost-effective biomarkers to facilitate clinical 
management [72].
Research is ongoing in relation to biomarkers, with a 
number of promising developments. The presence of 
neutrophils in the epithelium is a marker of histological 
activity and is associated with higher faecal calprotectin 
levels [73]. Gene microarray experiments have revealed a 
signature CD8 T-cell transcriptional profile that may be 
predictive of the need for future treatment escalation, 
which may allow for the potential of a worsening disease 
evolution to be recognised at diagnosis of UC [19]. Pre-
liminary findings suggest that expression of the periph-
eral blood T-cell surface marker CD25 and levels of inter-
leukin-5 secretion in vitro may predict response to anti-
TNF drugs [74].
Clinical data demonstrating and validating correla-
tions between inflammatory mediators and their metabo-
lites with levels of disease severity in UC could form a 
useful basis for the development of routine tests to inform 
the likely effectiveness of treatments [71, 74].
More generally, biomarkers that predict a lack of re-
sponse may prove to be more useful in clinical practice 
than those predictive of a positive response. Biomarkers 
that differentiate drug classes by efficacy in individual pa-
tients would also be of great value to practising physi-
cians.
6. There is an ongoing need to update treatment strate-
gies including the introduction of novel UC therapies. 
Treatment guidelines recommend the best available prac-
tice at the time of their development. These guidelines 
must, therefore, be continually reviewed and revised in 
light of emerging new treatments and approaches. The 
ECCO e-Guide reflects this need [75], being a web-based 
collection of treatment algorithms that is continually up-
dated based upon the latest ECCO guidelines [76].
7. Optimal treatment strategies for UC should take into 
account recommendations and guidelines. Treatment 
recommendations offer a number of benefits, providing 
management guidelines based upon best-available evi-
dence, and providing a useful additional source of dis-
ease education for physicians. There are influential 
guidelines for the treatment of UC, including ECCO 
guidelines [76] and the Toronto consensus [77], which 
contain treatment recommendations based upon a vari-
ety of factors, including disease severity, distribution and 
prior treatment.
It should be recognised, however, that the utilisation 
of guidelines and treatment algorithms in clinical practice 
may not be possible, as they may not be directly applicable 
to individual patients with complex presentations.
Patient-Focused Unmet Needs Statements
8. PROs beyond stool frequency and rectal bleeding need 
to be defined and validated to provide comparable results 
across studies. PROs are important tools for determining 
disease severity and the success of a treatment, enabling 
assessment of the patient’s perspective on the impact of 
their disease in addition to measurements of physical 
symptoms [78]. Assessing satisfaction in patients through 
PROs may positively influence quality of care in IBD [79].
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PROs should be standardised, validated question-
naires that evaluate a patient’s perception of their health 
condition without clinical interpretation of that response 
[80]. They also have an increasingly important role in the 
evaluation and approval of new treatments for IBDs [81]. 
Currently, however, no UC PROs have been validated by 
regulatory authorities for this purpose [81].
In one clinical investigation, a 2-item, Mayo Clinic 
Score-derived PRO consisting of rectal bleeding and 
stool frequency scores yielded statistically significant dif-
ferences between active treatment and placebo groups 
when combined with an endoscopy subscore [81]. A co-
primary endpoint such as this may provide a suitable 
outcome measure for UC clinical trial use, while the 
lengthy process of developing a validated PRO is under-
way [81].
9. Patients’ perspectives and expectations are poorly un-
derstood. The impact of IBD is not only felt by patients 
during flares of their disease, but between flares too, with 
some estimates suggesting rates of anxiety as high as 35% 
during periods of remission [82]. Over time, in addition 
to the physical symptoms of disease (such as fatigue, a 
common and bothersome symptom that may affect pa-
tients’ mood) [83], the psychological impact can have an 
increasingly important effect on patients’ well-being. A 
survey of UC patients in the United States evaluating the 
psychological impact of the disease revealed that in excess 
of 80% of respondents worried about the long-term ef-
fects of UC, and that having UC made life more stressful 
[33]. Furthermore, 62–70% of respondents reported feel-
ings of embarrassment or depression related to their dis-
ease [84].
The impact of UC on patient well-being may be great-
er than that of other chronic diseases [85]. In total, 53% 
of respondents to the same patient survey reported that 
they felt their UC was taking over their life; a markedly 
higher percentage than is seen with chronic conditions 
such as asthma (19%), migraine (37%) or rheumatoid ar-
thritis (44%) [84].
It is, therefore, important that physicians develop close 
and effective relations with their patients, that they re-
main aware of their patients’ psychological well-being, 
and that medical care be integrated with psychological 
and social support [86–88].
10. Active involvement of patients in clinical decision 
making improves patient satisfaction and probably dis-
ease outcomes. The treatment and control of UC is met 
with varying degrees of success, and therapeutic decision 
making is usually symptomatology-led. It is increasingly 
the case, however, that patients are becoming more in-
volved in the management of their disease [89]. In fact, 
98% of patients in a study exploring patient empower-
ment considered active involvement in decision making 
to be quite or very important [90]. Patient empowerment 
has also been shown to improve adherence, as demon-
strated by a group of UC patients receiving 5-ASA ther-
apy who had access to a web-based education and self-
treatment package [91]. These same patients demon-
strated improved quality of life and reduced relapse 
duration compared to a control group receiving usual 
care [91].
Whether such improvements in patient outcomes are 
directly related to patient involvement in treatment deci-
sion-making or are an artefact of, for example, better ad-
herence in empowered patients is unknown. However, 
increased involvement seems likely to positively influ-
ence a patient’s satisfaction in their treatment. An expert 
consensus process initiated by the International Organi-
zation for the Study of Inflammatory Bowel Disease sup-
ported the use of PROs in defining remission, and ac-
knowledged the need to address a patient’s individual 
treatment goals [92].
11. Patients may reset their tolerance threshold to the 
symptoms and this can result in lower treatment expecta-
tions. A study of IBD patients in Japan demonstrated that 
while increasing medication was the most effective way to 
improve symptoms during a disease flare, making dietary 
changes and sleeping more were the most commonly 
used coping strategies [93]. This suggests that some pa-
tients resort to lifestyle modifications as a way of coping 
with their symptoms, instead of or in addition to receiv-
ing additional medical treatments.
Even when disease activity remains unchanged, pa-
tient perceptions of their disease can be improved through 
the use of psychotherapy. This has been demonstrated in 
a randomised control study examining stress manage-
ment in a cohort of patients with IBD showing continu-
ous disease activity or recent relapse, where professional 
stress management psychotherapy significantly improved 
disease-specific quality of life, in spite of unaltered disease 
activity [94].
Discussion
A thorough review of the literature formed the basis of 
an initial 15 statements, which were subsequently ex-
panded to 18 statements, relating to medical unmet needs 
in UC, and a modified Delphi process was used to estab-
lish consensus among a panel of European-based gastro-
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enterologists with expertise in IBD. A 2nd Expert Panel 
meeting identified a number of additional unmet needs. 
These additional unmet needs form the basis of an up-
dated systematic literature review. The modified Delphi 
process resulted in 12 unmet needs consensus statements, 
categorised as disease-, practice- or patient-focused.
Of the 18 initial medical unmet needs statements, 4 
relate to UC patients’ inability to lead a normal life. The 
present research brings a clear message that better under-
standing is needed of patients’ views regarding the impact 
of UC and its treatment on their lives [32, 33]. A further 
3 of the 18 consensus statements relate to the importance 
of early diagnosis and treatment of UC. The onset of UC 
may be insidious and in many individuals, symptoms 
may be present for weeks or longer before clinician advice 
is sought [1]. A good level of awareness of UC is needed 
in primary care settings to ensure that patients are re-
ferred to specialist care as soon as possible so as to mini-
mise delays in diagnosis. Although there is no evidence 
that duration of UC at the start of TNF inhibitor therapy 
has any impact on long-term disease control, there may 
be a case for early aggressive management using this class 
of drugs [53]. It is known that early intervention is ben-
eficial in CD [95]; however, further research is required 
to ascertain whether this is also the case in UC. Further-
more, optimal outcome measures in studies that investi-
gate disease activity over the longer term are unknown; 
corticosteroid dependency, hospitalisations, disability 
and surgery are candidate proxies.
Seven of the 18 unmet needs statements address draw-
backs of existing UC treatments. 5-ASA is well estab-
lished as the mainstay of treatment for mild-to-moderate 
cases; however, long-term adherence to this drug seems 
difficult to maintain. While corticosteroids may be high-
ly effective induction agents, they are inappropriate as 
maintenance therapies [5]. Thiopurines, on the other 
hand, are not efficacious as induction agents [95]. They 
are effective in combination with anti-TNF therapy in 
some patients. However, in a clinical trial comparing in-
fliximab monotherapy, azathioprine monotherapy, and 
combination therapy with both these agents, less than 
40% of patients in the combination therapy group 
achieved corticosteroid-free remission at 16 weeks, and 
in monotherapy groups this endpoint was achieved in less 
than one quarter patients [11].
The next 3 unmet needs statements highlight the need 
for new therapeutic options in UC. In the management of 
this disease, long-term control is paramount and possibly 
more important than rapid improvement of symptoms, 
although patients with severe UC favour fast-acting ther-
apy. While some patients may prefer oral over parenteral 
therapies, efficacy is their main concern [34]. There is an 
unmet need for small molecule drugs that confer compa-
rable efficacy to injections/infusions [61]. The final state-
ment calls for more investigator collaboration and lobby-
ing to promote continued investment in the education of 
healthcare practitioners and raise awareness of the treat-
ment of UC through the development, publication and 
dissemination of scientific research.
The additional 12 disease-focused unmet needs state-
ment agreed serve to highlight gaps in clinicians’ knowl-
edge of the natural history of UC, including unsolved 
questions around the aetiology of the disease, and hetero-
geneous patterns of progression, as well as idiosyncrasies 
in response to treatments. It is apparent that significant 
knowledge is required on how current and new therapies 
may impact or alter the disease course of UC.
The practice-focused unmet needs statements consid-
er the need for new therapies that are able to change the 
disease course of UC, as well as emphasising the degree to 
which clinical practice diverges from recommendations 
and guidelines. While it is apparent that guidelines are 
always evolving, the need for treatment strategies to re-
flect guidelines is identified. These statements also em-
phasise the need for effective, practical biomarkers; re-
search into a number of candidates is ongoing.
Considering unmet needs from the patient perspective 
raises the need for validated PROs to be developed for use 
in future clinical trials, given that no regulator-approved, 
validated PROs currently exist. There is also a clear desire 
for patients to be more involved in the management of 
their disease, which is supported by positive data suggest-
ing that this can lead to improvements in both adherence 
and disease outcomes. Finally, consensus was gained that 
patients’ expectations vary over time as they adapt to liv-
ing with UC, which may affect their subjective responses 
to treatment.
It should be acknowledged that the unmet needs state-
ments presented in this study are the opinion of a small 
group of gastroenterologists, which can be considered a 
limitation of this study. The consensus reached following 
in-depth discussions was, however, supported by an ex-
tensive literature review.
In conclusion, extensive literature reviews and Delphi 
exercises identified a considerable number of outstand-
ing problems in the current management of UC. These 
findings can help provide direction for future research 
and act as an impetus for further improving disease man-
agement and further engaging UC patients in setting 
goals and other treatment-related decisions.
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